📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-10-08 22:46
0 analysed today
FollowTelegram
0
Today
151,433
All-time analysed
43,376
Positive
6,732
Negative
92,513
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
8 announcements match the current filters (relevance ≥ 5).
CRISIL Upgrades Asarfi Hospital's Bank Loan Rating to 'BBB/Stable' on ₹60 Cr Facilities
CRISIL Ratings has upgraded the long-term bank facilities of Asarfi Hospital Limited to 'CRISIL BBB/Stable' from 'CRISIL BBB-/Stable' and assigned a short-term rating of 'CRISIL A3+'. The rated bank loan facilities have also been enhanced to ₹60 crore from ₹46.5 crore. The upgrade is driven by a 32% increase in ARPOB, improved cancer unit occupancy from 30% in FY25 to 42% in FY26, and operating margins holding steady at 20-21%. Net cash accruals grew to ₹28 crore in FY26 compared to ₹23 crore in FY25, supporting a comfortable capital structure with debt-to-equity below 1x.
Confidence: HIGH
What changedCRISIL upgraded Asarfi Hospital's long-term rating by one notch to BBB/Stable and assigned an A3+ short-term rating, while expanding rated bank facilities from ₹46.5 crore to ₹60 crore.
Why it mattersA higher credit rating lowers borrowing costs and validates operational improvements, including rising ARPOB, higher cancer unit occupancy, and stable ~20% margins.
Enhanced Bank Loan Facilities: ₹60 CroreRated Bank Facilities vs TTM Revenue: ~32.6%FY26 Operating Income: ₹170.31 croreInterest Coverage (FY26): 8.43 timesNet Cash Accruals (FY26): Rs 28 crore
📅 Short termPositive sentiment from credit validation and potentially lower interest spreads on the company's ₹60 crore bank lines.
📈 Long termReflects improving operational scale and financial discipline; sustaining >20% margins and managing working capital will be essential to reach the rating upgrade trigger of ₹35 crore cash accruals.
⚠ Risk flags
- Geographic concentration risks with operations restricted primarily to Dhanbad, Jharkhand
- High working capital intensity with GCA around 150 days and 50-55% revenue tied to government schemes/PSUs
Key Highlights
Long-term credit rating upgraded to CRISIL BBB/Stable from CRISIL BBB-/Stable; short-term rating assigned at CRISIL A3+
Total bank loan facilities rated enhanced to ₹60 crore from ₹46.5 crore
Cancer unit occupancy improved to 42% in FY26 compared to 30% in FY25, alongside a 32% rise in ARPOB
Net cash accruals increased to ₹28 crore in FY26 from ₹23 crore in FY25, with interest coverage at 8.43 times
Operating income reported at ₹170.31 crore in FY26 vs ₹121.39 crore in FY25, with gearing at 0.58 times
👀 What to Watch
Track working capital cycle improvements, specifically overdue receivables from government schemes, and monitor the planned bed capacity ramp-up towards 500 beds.
Asarfi Hospital Approves Migration to BSE Main Board and Proposed Listing on NSE
Asarfi Hospital Limited's Board of Directors has approved the migration of the company from the BSE SME platform to the BSE Main Board, along with a proposed direct listing on the NSE, subject to shareholder and regulatory approvals. The company has scheduled its 21st Annual General Meeting (AGM) for September 18, 2026, with the e-voting cut-off date set as September 11, 2026. Additionally, the Board re-appointed Director Gopal Singh (retiring by rotation) and approved the appointment of Ashutosh Kumar Sinha & Co. as Cost Auditor for FY 2026-27.
Confidence: HIGH
What changedThe Board approved the formal proposal to migrate from the SME platform to the BSE Main Board and seek NSE listing.
Why it mattersGraduating to the Main Board and listing on the NSE removes SME lot-size trading constraints, significantly improving stock liquidity, institutional participation potential, and overall visibility.
AGM Date: September 18, 2026E-voting Cut-off Date: September 11, 2026Book Closure Window: September 05, 2026 to September 18, 2026
📅 Short termShareholders will vote on the migration resolution ahead of/during the AGM on September 18, 2026.
📈 Long termListing on the BSE Main Board and NSE can expand institutional investor access and trading volumes over the medium to long term.
⚠ Risk flags
- Subject to shareholder approval and regulatory/exchange approvals for Main Board migration and NSE listing.
Key Highlights
Approved migration from BSE SME platform to BSE Main Board and proposed listing on NSE, subject to shareholder approvals
21st Annual General Meeting (AGM) scheduled for Friday, September 18, 2026
Book closure fixed from September 05, 2026 to September 18, 2026; E-voting cut-off date set to September 11, 2026
Appointed M/s Ashutosh Kumar Sinha & Co. as Cost Auditor for F.Y. 2026-27
👀 What to Watch
Track shareholder voting outcomes at the upcoming AGM on September 18, 2026, followed by subsequent regulatory and exchange approval timelines for Main Board and NSE listing.
33% Revenue Growth: Asarfi Hospital Q1 FY27 Revenue at ₹47.53 Cr, PAT up 37% YoY
Asarfi Hospital reported a strong performance for Q1 FY27 with consolidated revenue growing 33% YoY to ₹47.53 Cr, which accounts for approximately 27.6% of its TTM revenue. Profitability showed significant improvement as PAT rose 37% YoY to ₹4.27 Cr, supported by a healthy EBITDA margin of 20%. Growth was driven by a 44% surge in OPD revenue and improved realizations, with the Cancer Unit achieving a high ARPOB of ₹31,892. The company continues its trajectory toward expanding its total capacity to 500 beds by March 2026.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, demonstrating robust double-digit growth in both top-line and bottom-line metrics compared to the previous year.
Why it mattersThe results validate the company's ability to scale its specialized healthcare services in the Dhanbad region and maintain healthy margins despite industry-wide cost pressures.
Revenue (Q1 FY27): ₹47.53 CrRevenue vs TTM: 27.6%PAT (Q1 FY27): ₹4.27 CrEBITDA Margin: 20%ARPOB (Cancer Unit): ₹31,892OPD Revenue Growth: 44% YoY
📅 Short termThe stock is likely to react positively in the short term due to strong earnings growth and margin stability.
📈 Long termLong-term value depends on the successful expansion to 500 beds and the ability to manage collection cycles from government-linked schemes.
⚠ Risk flags
- Elongated collection cycles from government and corporate tie-ups
- Price caps on government schemes limiting revenue per bed
Key Highlights
Consolidated revenue increased 33% YoY to ₹47.53 Cr for the quarter ended June 30, 2026.
Net profit (PAT) grew 37% YoY to ₹4.27 Cr from ₹3.12 Cr in the corresponding quarter of the previous year.
OPD revenue grew by 44% YoY, while IPD revenue increased by 31% YoY, indicating strong patient volume growth.
Average Revenue Per Occupied Bed (ARPOB) reached ₹31,892 for the Cancer Unit and ₹23,498 for the Super-Specialty unit.
EBITDA margin remained stable at 20%, driven by high-acuity specialties including Cardiology and Neurology.
👀 What to Watch
Investors should monitor the execution timeline for the remaining bed capacity expansion (from 315 to 500 beds) and the operationalization of the multi-organ transplant unit, which are key long-term growth drivers.
33% YoY Revenue Growth in Q1 FY27; Asarfi Hospital Reports Rs 4.27 Cr PAT
Asarfi Hospital reported a strong start to FY27 with standalone revenue growing 33% YoY to Rs 47.34 Cr. Profit After Tax (PAT) also increased by 33% to Rs 4.27 Cr, maintaining a steady PAT margin of 9%. Growth was primarily driven by a 44% surge in OPD revenue and a 31% rise in IPD revenue, supported by improved realizations in high-acuity specialties like Cardiology and Oncology. The company maintained an EBITDA margin of 20%, reflecting operational efficiency despite scaling.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial results, demonstrating a significant step-up in quarterly revenue and profitability compared to the same period last year.
Why it mattersThe results validate the company's strategy of improving the case mix toward high-margin oncology and super-specialty services, which is reflected in the rising ARPOB and sustained 20% EBITDA margins.
Revenue (Q1 FY27): Rs 47.34 CrPAT (Q1 FY27): Rs 4.27 CrRevenue Growth (YoY): 33%EBITDA Margin: 20%ARPOB (Cancer Unit): Rs 31,892Q1 Revenue vs TTM Revenue: 27.5%
📅 Short termThe stock may see positive sentiment in the coming days as the market reacts to the 33% growth in both top-line and bottom-line.
📈 Long termStructural growth remains tied to the successful expansion of bed capacity and the operationalization of the Gleneagles partnership for transplants, which could further re-rate margins.
⚠ Risk flags
- High dependence on government schemes with price caps
- Potential liquidity risks from elongated collection cycles in corporate/government tie-ups
Key Highlights
Standalone Revenue from operations increased 33% YoY to Rs 47.34 Cr in Q1 FY27
EBITDA grew 34% YoY to Rs 9.42 Cr with a stable margin of 20%
OPD revenue showed significant momentum with 44% YoY growth compared to Q1 FY26
ARPOB for the Cancer Unit reached Rs 31,892, outperforming the Super-Specialty unit's Rs 23,498
Basic and Diluted EPS for the quarter improved to Rs 2.17 from Rs 1.62 in the year-ago period
👀 What to Watch
Monitor the execution timeline for the bed capacity expansion to 500 beds by March 2026 and the launch of the multi-organ transplant unit, which are key for sustaining this growth trajectory.
33.2% Revenue Growth in Q1 FY27; Asarfi Hospital Reports Rs 4.3 Cr PAT
Asarfi Hospital reported a strong Q1 FY27 with consolidated revenue growing 33.2% YoY to Rs 47.5 Cr and PAT increasing 36.7% to Rs 4.3 Cr. The Super-Specialty unit saw a 21% YoY increase in ARPOB to Rs 23,498, despite a slight dip in occupancy to 59% due to bed additions. The Cancer Hospital unit showed significant improvement in occupancy, rising to 56% from 42% YoY. The company is on track for its 500-bed expansion target by March 2026, supported by a 28% increase in total surgery volumes.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial performance, showing strong top-line and bottom-line growth alongside improved operational metrics in the cancer unit.
Why it mattersThe results demonstrate the company's ability to scale its new cancer unit and improve realizations (ARPOB) in its core super-specialty business, supporting its regional leadership in Jharkhand.
Q1 Revenue: Rs 47.53 CrQ1 PAT: Rs 4.27 CrRevenue vs TTM Revenue: 27.6%Super-Specialty ARPOB: Rs 23,498Cancer Unit Occupancy: 56%Target Bed Capacity: 500 beds
📅 Short termPositive sentiment is expected as the company maintains high growth rates and stable margins while improving occupancy in the newer cancer unit.
📈 Long termStructural growth is driven by the planned 58% increase in bed capacity (to 500 beds) and the entry into high-value transplant services, which could re-rate the business.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Elongated collection cycles from government schemes
- Temporary ARPOB dilution from new bed additions
- Execution risk in the multi-organ transplant unit launch
Key Highlights
Consolidated Revenue grew 33.2% YoY to Rs 47.53 Cr in Q1 FY27
PAT increased by 36.7% YoY to Rs 4.27 Cr, maintaining a 9.0% margin
Super-Specialty ARPOB rose 21% YoY to Rs 23,498 from Rs 19,398
Cancer Hospital occupancy improved significantly to 56% from 42% YoY
Total surgery count increased by 28% YoY to 1,980 procedures
👀 What to Watch
Monitor the execution timeline for the remaining bed expansion to 500 beds by March 2026 and the operationalization of the multi-organ transplant unit in partnership with Gleneagles.
Asarfi Hospital Q1 PAT Rises 33% YoY to ₹4.27 Cr; Revenue Grows to ₹47.34 Cr
Asarfi Hospital reported a strong Q1 FY27 with revenue growing 32.7% YoY to ₹47.34 Cr, driven by its dominant position in the Dhanbad region. Net profit increased 33.4% YoY to ₹4.27 Cr, maintaining a steady net margin of approximately 9%. However, trade receivables surged to ₹64.65 Cr, representing nearly 1.4x the quarterly revenue, which highlights ongoing working capital pressure from government scheme tie-ups. The company continues its transition toward a 500-bed capacity, evidenced by a 125% increase in Capital Work-in-Progress (CWIP) since March 2026.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, showing sustained double-digit growth in revenue and profitability while continuing its capital expenditure for bed expansion.
Why it mattersThe results confirm the company's ability to scale in the underserved Jharkhand healthcare market, though the rising receivables highlight the financial cost of serving government-backed patient segments.
Revenue (Q1 FY27): ₹47.34 CrPAT (Q1 FY27): ₹4.27 CrTrade Receivables: ₹64.65 CrReceivables vs TTM Revenue: 37.6%EPS (Basic): ₹2.17
📅 Short termThe stock may see positive sentiment due to strong YoY growth and stable margins, though the high receivable build-up might temper enthusiasm for value-focused investors.
📈 Long termStructural growth remains tied to the successful expansion from 315 to 500 beds and the ability to improve ARPOB through high-end services like organ transplants.
⚠ Risk flags
- High trade receivables (₹64.65 Cr) indicating potential liquidity stress
- Concentration risk in government schemes with capped pricing
- Elongated collection cycles exceeding 6 months
Key Highlights
Revenue from operations increased 32.7% YoY to ₹47.34 Cr from ₹35.66 Cr in Q1 FY26.
Net Profit (PAT) grew 33.4% YoY to ₹4.27 Cr compared to ₹3.20 Cr in the same period last year.
Trade Receivables rose significantly to ₹64.65 Cr from ₹54.07 Cr as of March 31, 2026.
Capital Work-in-Progress (CWIP) increased to ₹3.97 Cr from ₹1.76 Cr, indicating ongoing facility expansion.
Employee benefit expenses rose 36% YoY to ₹7.86 Cr, reflecting increased clinical and support staff for scaling operations.
👀 What to Watch
Monitor the collection efficiency of trade receivables (₹64.65 Cr), as delays in government scheme payments could impact liquidity. Watch for the operationalization of the expanded bed capacity and the launch of the multi-organ transplant unit.
Rs 47.34 Cr Revenue: Asarfi Hospital Reports 33% YoY Growth in Q1 FY27 Results
Asarfi Hospital reported a strong start to FY27 with revenue from operations growing 32.7% YoY to Rs 47.34 Cr. Net profit for the quarter rose 33.4% YoY to Rs 4.27 Cr, maintaining a steady margin profile. However, trade receivables increased significantly by Rs 10.58 Cr during the quarter to reach Rs 64.65 Cr, reflecting the company's known challenge with elongated collection cycles from government schemes. Capital Work-in-Progress (CWIP) increased to Rs 3.97 Cr, signaling continued progress on the planned expansion to 500 beds.
Confidence: HIGH
What changedThe company has reported its Q1 FY27 financial results, demonstrating sustained double-digit growth in revenue and profitability compared to the previous year.
Why it mattersThe results confirm that the company is tracking well against its 23% expected growth rate, though the rising receivables highlight a persistent liquidity risk inherent in its government-heavy client mix.
Revenue (Q1 FY27): Rs 47.34 CrPAT (Q1 FY27): Rs 4.27 CrYoY Revenue Growth: 32.7%Receivables vs TTM Revenue: 37.6%Total Debt (Long + Short term): Rs 54.80 Cr
📅 Short termThe stock may see positive sentiment due to strong YoY growth and margin stability, though the increase in receivables may temper enthusiasm.
📈 Long termThe long-term outlook depends on the successful execution of the bed expansion to 500 units and the ability to diversify revenue away from low-margin government schemes.
⚠ Risk flags
- High trade receivables (Rs 64.65 Cr) relative to quarterly revenue
- Liquidity risk due to elongated collection cycles
- Revenue concentration in government and corporate tie-ups
Key Highlights
Revenue from operations increased 32.7% YoY to Rs 47.34 Cr compared to Rs 35.66 Cr in June 2025.
Net Profit after tax grew to Rs 4.27 Cr, up from Rs 3.20 Cr in the corresponding previous quarter.
Trade receivables spiked to Rs 64.65 Cr as of June 30, 2026, up from Rs 54.07 Cr in March 2026.
Capital Work-in-Progress increased by 125% to Rs 3.97 Cr from Rs 1.76 Cr in the previous quarter.
Basic and Diluted EPS improved to Rs 2.17 for the quarter from Rs 1.62 YoY.
👀 What to Watch
Investors should monitor the occupancy levels as the company scales toward its 500-bed target by March 2026 and track if the multi-organ transplant unit partnership with Gleneagles begins contributing to ARPOB growth.
₹400 Cr Revenue Target by FY28: Asarfi Hospital Outlines Expansion & Main Board Migration
Asarfi Hospital has set an ambitious long-term revenue target of ₹400 crore by FY2028, a 132% increase over its current TTM revenue of ₹172 crore. The company is diversifying its healthcare ecosystem by bidding for a 100-seat Medical College under a PPP model and evaluating the acquisition of a 70-bed regional hospital. Management is also preparing for migration from the SME platform to the Main Board, which could enhance liquidity and institutional interest. Key growth drivers identified include Cardiology, Oncology, and Neurosurgery, supported by a planned Bone Marrow Transplant facility.
Confidence: HIGH
What changedThe company has provided specific long-term revenue guidance and announced its intent to move to the Main Board while expanding into medical education.
Why it mattersThe ₹400 crore target implies a significant growth trajectory (approx. 24% CAGR); the shift to the Main Board and the addition of a medical college could structurally re-rate the company's valuation and operational scale.
FY2028 Revenue Target: ₹400 croreTarget vs TTM Revenue: 232%Proposed Medical College Seats: 100Potential Acquisition Size: 70 bedsPlanned Bed Capacity (Mar 2026): 500 beds
📅 Short termPositive sentiment is expected due to the clear growth roadmap and the prestige associated with Main Board migration.
📈 Long termIf the company successfully scales to 500 beds and integrates the medical college, it will transition from a regional player to a major integrated healthcare provider in Jharkhand.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk on the PPP medical college bid
- Integration risk for the proposed 70-bed acquisition
- High dependence on government scheme pricing
Key Highlights
Targeting ₹400 crore revenue by FY2028, compared to the current TTM revenue of ₹172 crore
Evaluating the acquisition of a 70-bed hospital to strengthen regional presence in Jharkhand
Bidding for a 100-seat Medical College under the Public-Private Partnership (PPP) model
Planned expansion to 500 total beds by March 2026, up from the current 315-bed capacity
Initiated preparatory activities for migration to the Main Board of the stock exchange
👀 What to Watch
Monitor the outcome of the 100-seat Medical College bid and the definitive agreement for the 70-bed hospital acquisition as these will be key catalysts for the FY28 revenue target.
